Actinium Pharmaceuticals, Inc. (NYSE:ATNM) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Actinium Pharmaceuticals, Inc. (NYSE:ATNM) have received an average rating of “Moderate Buy” from the five brokerages that are presently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $11.40.

A number of brokerages recently issued reports on ATNM. HC Wainwright restated a “buy” rating and set a $4.00 price target on shares of Actinium Pharmaceuticals in a report on Friday. Maxim Group dropped their price target on Actinium Pharmaceuticals from $30.00 to $5.00 and set a “buy” rating for the company in a research note on Tuesday, August 6th. B. Riley cut shares of Actinium Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $16.00 to $2.00 in a research report on Wednesday, August 7th. Finally, StockNews.com cut shares of Actinium Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, November 11th.

Institutional Trading of Actinium Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Los Angeles Capital Management LLC purchased a new stake in Actinium Pharmaceuticals in the third quarter worth about $322,000. XTX Topco Ltd purchased a new stake in shares of Actinium Pharmaceuticals in the 3rd quarter worth approximately $268,000. Marshall Wace LLP raised its stake in Actinium Pharmaceuticals by 67.9% during the second quarter. Marshall Wace LLP now owns 256,026 shares of the company’s stock valued at $1,895,000 after buying an additional 103,557 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Actinium Pharmaceuticals by 6.0% in the first quarter. Vanguard Group Inc. now owns 1,446,326 shares of the company’s stock worth $11,325,000 after acquiring an additional 82,113 shares in the last quarter. Finally, Virtu Financial LLC grew its stake in shares of Actinium Pharmaceuticals by 319.2% in the first quarter. Virtu Financial LLC now owns 82,029 shares of the company’s stock worth $642,000 after acquiring an additional 62,459 shares during the last quarter. 27.50% of the stock is owned by hedge funds and other institutional investors.

Actinium Pharmaceuticals Stock Performance

Shares of Actinium Pharmaceuticals stock opened at $1.50 on Tuesday. The company has a market cap of $46.79 million, a price-to-earnings ratio of -0.99 and a beta of 0.14. The stock has a fifty day moving average price of $1.79. Actinium Pharmaceuticals has a 12-month low of $1.33 and a 12-month high of $10.24.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML).